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Approach to Study Design
critical step in planning a successful study is choosing the
appropriate design to feasibly answer the clinical question at
hand. Although the research design depends on the ques-
tion, there are advantages and limitations to each type of design.
Furthermore, cost and time constraints as well as sample size con-
siderations may influence the choice of design. Understanding the
fundamental principles underlying the most common study designs
encountered in the field of clinical research is essential not only for
designing studies but also for the critical reading and appraisal of
the literature. Recognizing both the strengths and the inherent bi-
ases introduced by each particular study design will allow the clini-
cian to more accurately interpret results and, more importantly,
determine whether and how these results should be applied to
clinical practice. We provide an overview of common study designs,
discuss their advantages and disadvantages, and provide practical
examples from the prenatal diagnosis and ultrasound literature. In
addition, we highlight specific design considerations that need to
be built into the analysis of study results.
The Basics of Study Design
Figure 1 illustrates an algorithm for classifying clinical research de-
signs.1 Study designs can broadly be categorized as observational or
experimental. In observational studies, data are gathered by ob-
serving events and outcomes over time (either prospectively or ret-
rospectively) without any active manipulation of the exposure.
Observational studies can further be divided into descriptive and
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analytic based on the presence or absence of a comparison
group.2 Inherent to the observational nature of the design,
these studies are subject to the effects of bias and con-
founding. Both bias and confounding may threaten the in-
ternal validity of a study, which is a prerequisite for the
external validity, or generalizability, of the study results. 
Although careful design and analysis can minimize their
influences on the study results, their effects cannot com-
pletely be eliminated. For this reason, causal associations
should only be made with caution in observational studies.
Bias is defined as “any trend in the collection, analysis,
interpretation, publication, or review of data that can lead
to conclusions that are systematically different from the
truth.”3 Common types of bias include selection bias and
ascertainment bias. Selection bias occurs when there is a
systematic difference between the two groups being stud-
ied. For example, in a cohort study, because the exposure
is not manipulated by the investigator, the exposure group
may comprise patients with a particular set of characteris-
tics that differ from those of the nonexposure group,
thereby leading to spurious associations. Ascertainment
bias occurs when methods for measuring either the expo-
sure or outcome are different between the study groups.2
For example, in a case-control study evaluating risk fac-
tors for aneuploidy, measurement bias may exist if all cases
underwent amniocentesis for karyotype results, whereas
controls may have only undergone amniocentesis in the
presence of suspicious ultrasound findings. This type of bias
could potentially misclassify undiagnosed cases as controls.
Finally, the effect of confounding must be considered.
A confounder is defined as a third variable that is related
to both the exposure and outcome but is not on the causal
pathway toward the outcome. The presence of one or
more confounders can blur associations found in the
study, thereby limiting inferences of cause and effect. The
process of randomization in a randomized controlled trial
serves to eliminate the effect of both known and unknown
confounders. Observational studies, on the other hand,
often require more sophisticated methods to handle po-
tential confounders. From a design perspective, methods
such as specification and matching may reduce the effect
of potential confounders. Specification restricts enroll-
ment to patients with a particular value for a potential con-
founder, whereas matching selects cases and controls
based on the presence or absence of the potential con-
founder. From a statistical perspective, confounding can
be handled by methods including stratification, adjusted
analyses, and propensity scores.4 Despite these methods,
residual confounding cannot be eliminated in observa-
tional studies.
In their most basic forms, experimental study designs
involve an intervention that is applied to patients at the be-
ginning of the study by the investigator, either by random
or nonrandom allocation. The patients are then followed
forward in time to determine whether they develop the
outcome of interest. The double-blind randomized con-
trolled trial is considered the reference standard study de-
sign in clinical research because it is the only effective
means of avoiding bias and confounding.
The key features of the most commonly used research
designs are discussed in the following sections.
Descriptive Study Designs
Descriptive studies are observational studies that lack a
comparison group. As is inherent in the name, the goal of
the descriptive study is to “describe” features of a condi-
tion and the characteristics of those affected. Grimes and
Schulz5 described a pentad of W questions that good de-
scriptive research should be able to answer: Who? What?
Why? When? and Where? By answering these questions,
descriptive studies can be used to report new diseases or
syndromes, evaluate characteristics of affected individuals,
and follow trends in health. A major pitfall in the descrip-
tive study design is that, because of the lack of a compari-
son group, causal associations cannot be evaluated. Despite
this drawback, descriptive studies can be extremely useful
in generating hypotheses that can then be tested in future
analytic or experimental studies.5,6
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Figure 1. Algorithm for classifying types of clinical research design.
Adapted from Schulz and Grimes.1
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There are 3 main types of descriptive studies encoun-
tered in the prenatal diagnosis literature: case reports, case
series, and cross-sectional studies. 
Case Reports and Case Series
A case report provides a detailed description of a clinical
case, typically an unusual or uncommon disease, compli-
cation, or constellation of symptoms. Although a case re-
port details findings from an individual patient, a case series
describes findings from an aggregate of similar cases.3 This
type of study can be especially helpful when evaluating
characteristics of a rare disease. 
Cross-sectional Studies
The cross-sectional study design can be described as a
“snapshot” view of a sample at one point in time. In this
type of study, both exposure and outcome measurements
are taken at the same time without a follow-up period.
From these measurements, the prevalence of a disease or
condition can be estimated.4,5 The relative prevalence of
an outcome can also be calculated in these studies by com-
paring patients with and without the exposure of interest.
For this reason, a cross-sectional study is commonly re-
ferred to as a prevalence study. Because there is no longi-
tudinal follow-up incorporated into this study design, the
disease incidence cannot be calculated, and temporal rela-
tionships cannot be established. Despite these limitations,
the associations and disease distributions observed in
cross-sectional studies can be hypothesis-generating for
future investigations.
An example of a cross-sectional study design in the
ultrasound and prenatal diagnosis literature is in the con-
struction of a fetal growth curve by Alexander et al.7 They
used population-based data from more than 3 million live
births in the United States to create a national reference
for fetal growth. By using large-scale data from the entire
United States, Alexander et al7 were able to generate a fetal
growth curve that was anticipated to be more generalizable
than prior growth curves, which had been constructed in
various subpopulations and geographic regions. Intrinsic
to the cross-sectional design, there was no longitudinal fol-
low-up of estimated fetal weight over time, but instead,
birth weight was captured at a single point in time for each
patient delivering during the study period. Although
growth curves derived from these cross-sectional studies
cannot evaluate patterns of fetal growth or causal mecha-
nisms for abnormal growth, they have certainly been used
in the generation and testing of multiple hypotheses over
the years. An important consideration in cross-sectional
studies is that only one measurement per individual patient
should be included in the data set to ensure that these
measurements are independent. Prenatal diagnostic im-
aging studies commonly use cross-sectional study designs,
and several examples of these have been published in the
Journal of Ultrasound in Medicine.
Analytic Study Designs
The analytic study design differs from the descriptive study
design in that it has a comparison or control group, which
allows measures of association such as relative risks and
odds ratios to be estimated. Analytic study designs are
classically regarded as more powerful than their descrip-
tive counterparts and have been rated as higher-quality
clinical evidence by the US Preventive Services Task
Force8 in the hierarchy of study designs. Analytic study
designs are divided into cohort and case-control studies
based on classification of study groups by exposure or out-
come, respectively.
Cohort Studies
The cohort study is a type of analytic study in which pa-
tients with an exposure are compared to those without the
exposure with respect to one or more outcomes of interest.
The defining feature of this type of design is that the pa-
tients are followed forward in time from exposure to out-
come. From these data, the incidence of the outcome can
be calculated because all patients are considered “disease
free” at the start of the study. Although conceptually the
tracking of data in this type of study design is always mov-
ing forward in time, the actual collection of data can occur
prospectively or retrospectively. In the prospective cohort
study, eligible patients are identified on the basis of the
presence or absence of the exposure of interest and are fol-
lowed for a meaningful length of time with periodic as-
sessments of the outcome. In the retrospective cohort
study, assembly of the cohort and outcome determination
have already taken place. Existing data, such as medical
records and perinatal databases, are frequently used for this
type of study. Despite the retrospective data collection and
analysis, the cohort itself is still defined by the presence or
absence of exposure to the risk factor.4,9
Advantages of the cohort study include the ability to
calculate the disease incidence and evaluate the temporal
relationship between the exposure and outcome. Although
causal associations can be suggested, such associations
should only be made with caution because of the potential
for confounding by other measured and unmeasured vari-
ables. Multiple outcomes can also be evaluated in cohort
studies, although the statistical implications of multiple
J Ultrasound Med 2011; 30:1416–1423 1417
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comparisons must be considered. It is generally advisable
to determine primary and secondary associations before
initiating the study and to report all associations evaluated,
both significant and nonsignificant. Performing multiple
comparisons may result in significant associations by
chance alone. Another advantage to the cohort study is
that rare exposures can be studied by assembling a cohort
of individuals with uncommon exposures. Although
prospective studies allow a higher level of completeness in
evaluating the variables of interest, retrospective studies
are often of lower cost and much less time-consuming.4
Both prospective and retrospective cohort studies
have their unique disadvantages. Both are inefficient de-
signs for studying rare outcomes, and both are plagued with
the potential for incomplete data due to loss to follow-up. 
It is important to consider the reason for the loss to follow-
up because patients could be dropping out of the study
due to a factor that is related in some way to the outcome
of interest. In prospective cohort studies, the investiga-
tor has control over which variables are measured and
how they are defined, whereas retrospective studies are 
dependent on how the data were previously collected. 
In many cases these data have not been measured and
recorded in ways that are ideally suited to appropriately an-
swer the study question. Important potential confounding
variables may not be consistently recorded, thereby limit-
ing the use of these variables in adjusted analyses. Finally,
prospective studies may be time-consuming and costly, es-
pecially when there is a long lag time between the expo-
sure and disease onset.4,9 Fortunately, lag time is less of a
concern in perinatal research, given the finite and relatively
short length of pregnancy.
As with any study, it is important to have clear and
measurable definitions of both the exposure and outcome.
If the outcome is subjective, then the person assigning the
outcome should ideally be blinded to the patient’s expo-
sure status. Additionally, all patients in the cohort should
be at risk of developing the outcome.9 For example, in a
study of risk factors for postcesarean wound complications,
patients who deliver vaginally should not be included be-
cause they have no risk of developing the outcome.
In addition to being able to calculate the incidence of
an outcome in a cohort study, the strength of association
can also be determined and expressed as the relative risk
or odds ratio with the 95% confidence interval. Using a
classic 2 × 2 table of exposure and outcome, the formula
for relative risk is [a/(a + b)]/[c/(c + d)], defined as the
ratio of the outcome in exposed patients compared to un-
exposed patients (Table 1). A relative risk of greater than
1 indicates an increased risk of disease in the exposed
group, whereas a relative risk of less than 1 indicates a pos-
sible protective effect of the risk factor on the outcome of
interest. The further the relative risk is from 0 in either di-
rection, the stronger the association. For example, a rela-
tive risk of 2 indicates that patients with a specific risk
factor are 2-fold more likely to develop the outcome of in-
terest compared to those without the risk factor.2,10 When
translating reported relative risks into clinical practice, it is
important to remember the actual incidence of disease
(absolute risk). If the incidence of the outcome is ex-
tremely low (eg, 0.01%), then even a large relative risk (eg,
10.0) may not translate into a clinically meaningful in-
creased risk (eg, 0.1%). This interpretation is largely de-
pendent on the severity and implications of the outcome
of interest.
Finally, from cohort study data, one can determine the
additional risk of the outcome after exposure that is attrib-
utable to the risk factor being studied. This measure is
known as the attributable risk and is calculated by sub-
tracting the incidence of the disease in the unexposed
group from the incidence of disease in the exposed group.
The attributable risk is often considered a better measure
of individual risk than the relative risk, which is more of a
representation of the strength of association.10
Cohort studies are very common in the prenatal diag-
nosis and ultrasound literature. Retrospective studies are
often performed using ultrasound and perinatal databases.
Such databases may include ultrasound data entered at the
time of the examination as well as delivery and neonatal
outcome data entered at the time of or soon after delivery.
Although data collection is retrospective in nature, such
studies are classified as cohort studies according to the def-
inition of study groups based on exposure status. For ex-
ample, using a perinatal database of 72,373 patients who
presented for second-trimester sonography at a single in-
stitution, Hua at el11 performed a retrospective cohort
study to estimate the risk association between a single um-
bilical artery and adverse pregnancy outcomes. This study
estimated a relative risk of 1.7 for intrauterine growth re-
striction, 2.6 for preterm birth before 34 weeks, and 1.8 for
Goetzinger et al—Prenatal Diagnostic Imaging Studies: Approach to Study Design
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Table 1. Measures of Association in Cohort and Case-Control Studies
Outcome
Exposure Yes No Total
Yes a b a + b
No c d c + d
Total a + c b + d a + b + c + d
Relative risk = risk of an outcome in exposed/risk of an outcome 
in unexposed = (a/a + b)/(c/c + d). Odds ratio = odds of exposure in
cases/odds of exposure in controls = (a/c)/(b/d) = a × d/b × c.
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preterm birth before 37 weeks.11 In this study, the expo-
sure was defined as the presence or absence of a sono-
graphically diagnosed single umbilical artery, and multiple
adverse outcomes were studied. Although these results do
not prove causation, they suggest that a single umbilical ar-
tery is a risk factor for these adverse perinatal outcomes.
An example of a prospective cohort study is a recently
published study examining the association between the
ultrasound appearance of a cesarean hysterotomy scar in
nonpregnant women and the outcome of subsequent preg-
nancies.12 Three groups of patients were defined according
to the nature of their hysterotomy scars on transvaginal
sonography (exposure): intact scar, small defect, and large
defect. The primary outcome was uterine dehiscence or
uterine rupture (outcome). The methods of this study
show important principles in the design of prospective co-
hort studies, including the a priori clear definitions of ex-
posure and outcome and the blinding of clinical staff to the
ultrasound findings at the time of delivery to eliminate a
biased assessment of the outcome. Finally, only patients
with a prior cesarean delivery could be included in the
study to fulfill the cohort study criteria that all patients must
be at risk for the outcome of interest (uterine scar dehis-
cence).12 Although small in numbers, this prospective co-
hort study suggests a positive association between large
hysterotomy defects diagnosed by ultrasound and subse-
quent uterine dehiscence or rupture. This suggestion is
hypothesis-generating and may serve as a basis for fu-
ture larger-scale studies to definitively determine whether
the status of prepregnancy hysterotomy scars on trans-
vaginal sonography can accurately predict uterine dehis-
cence or rupture.
The cohort study design is particularly suited to many
prenatal screening and diagnostic ultrasound studies.
Case-Control Study
In contrast to the cohort study design in which patients are
selected according to the presence of the exposure, the
case-control study involves identifying patients with
(cases) and without (controls) the outcome of interest and
then looking backward in time to determine exposure. This
design is particularly advantageous when studying rare out-
comes or outcomes with long lag times. Although multi-
ple risk factors can be evaluated in a case-control study,
analysis is limited to a single outcome. Given that patients
are identified when the outcome has already occurred,
temporal relationships cannot be established using this
study design. Finally, because the number of cases is pre-
determined by virtue of the study design, the disease preva-
lence and incidence cannot be calculated.4
The odds ratio is the measure of association used in
case-control studies. It is defined as the odds of exposure in
patients with the disease compared to the odds of expo-
sure in patients without the disease. Using the classic 2 × 2
table, the odds ratio is given by a × d/b × c (Table 1). When
the outcome is rare, the odds ratio approximates the rela-
tive risk. Alternatively, when the outcome is common, the
odds ratio typically represents an exaggeration of the true
relative risk. Although relative risks are typically easier to
interpret than odds ratios, they cannot be reliably calcu-
lated in case-control studies. In other words, the number of
cases and controls in a case-control study is fixed by the in-
vestigator (usually equal), whereas there are likely far fewer
cases than controls in the overall population.10,13 Even if
the odds ratio indicates a strong association between an
outcome and a risk factor, it does not necessarily translate
into a strong discriminatory or predictive ability of that risk
factor. Mathematically, the odds ratio can be written in
terms of the true-positive fraction or sensitivity and the
false-positive fraction or 1 – specificity as odds ratio =
[true-positive fraction/(1 – true-positive fraction)] × [(1
– false-positive fraction)/false-positive fraction]. From this
equation, it can be deduced that more than one combina-
tion of true- and false-positive fractions can produce the
same odds ratio, showing the inconsistency in discrimina-
tion. Pepe et al14 showed that an odds ratio of tremendous
magnitude (eg, 171.0) is required to achieve adequate
discriminatory ability between true- and false-positives.
Therefore, for case-control studies in which prediction is
the primary goal, it is prudent to report false- and -negative
rates separately for binary risk factors. Alternatively, receiver
operating characteristic curves may be more appropriate
for continuous risk factors.14 Ultimately, the principle goal
of the study should drive the statistical analysis and re-
porting of the results.
One of the major limitations of the case-control study
is its inherent susceptibility to selection and ascertainment
biases. It is important to ensure that both cases and con-
trols are representative of the population of interest and
that patients designated controls are representative of the
population at risk for developing the outcome of interest.
It is particularly important to carefully consider the selec-
tion of controls. If controls did not undergo a diagnostic
test or procedure to rule out the outcome of interest, it is
possible that undiagnosed cases may actually be misclassi-
fied as controls.4,13 The most common form of ascertain-
ment bias in the case-control study is recall bias. Cases may
be more likely to recall an exposure compared to controls.
The classic example of recall bias in obstetrics is in terato-
gen research, in which mothers of neonates born with birth
J Ultrasound Med 2011; 30:1416–1423 1419
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defects are much more likely to have carefully considered
every possible exposure during pregnancy compared to
mothers with healthy neonates. This situation potentially
leads to false conclusions of positive associations between
exposures and outcomes.
The nested case-control study design is a modifica-
tion of the case-control design that may reduce bias. In this
design, cases and controls are drawn from a defined cohort
of patients. By definition, all patients in the cohort are dis-
ease free at entry into the study. Those who go on to de-
velop the outcome of interest become the cases, and a
random sample of the remaining patients who do not de-
velop the outcome of interest become the controls. To re-
duce confounding, controls are often matched to cases on
the basis of the presence or absence of one or more vari-
ables. This unique study design eliminates the potential se-
lection bias of controls coming from a population that is
different from that of cases. This study design is also useful
when measurement of variables may be costly or time-con-
suming. Rather than performing this measurement on all
patients in the cohort, archived samples or images can later
be analyzed only in patients selected as cases and con-
trols.4,15
A recently published study on placental morphome-
tric characteristics in pregnancies affected by intrauter-
ine growth restriction and preeclampsia16 is an example
of this type of study design. In this study, placental mor-
phometric assessment was performed on 13 patients with
preeclampsia, 7 patients with gestational hypertension, 
7 patients with intrauterine growth restriction, and 20 un-
complicated control pregnancies. Both cases and controls
were selected from a cohort of patients who were enrolled
in a prospective study evaluating the association between
first-trimester measures of placental dysfunction and ad-
verse pregnancy outcomes.16 Given the time- and labor-
intensive nature of placental morphometric assessment,
it would not be feasible to perform this test on all patients
in the cohort. Instead, the nested case-control study de-
sign provided a large cohort of representative patients
from which both cases and a subset of controls could be
identified.
Experimental Studies
Unlike observational studies in which the investigator has
no control of the exposure, experimental studies involve
assignment of the exposure by the investigator. The ability
to assign exposure provides the investigator control over
experimental studies that cannot be achieved in observa-
tional studies. However, interventional studies may not be
feasible for all research questions. For example, it may not
be ethical for an investigator to expose patients to a factor
likely to cause a deleterious outcome. Similarly, outcomes
with long lag times and the high costs associated with such
studies may make the experimental design unsuitable for a
particular question.
Interventional studies involving human patients are
termed clinical trials. Depending on whether patients
are randomly or nonrandomly assigned to the compar-
ison groups, clinical trials may be randomized or non-
randomized.
Randomized Controlled Trials
The randomized controlled trial is considered the refer-
ence standard for clinical research. It is the only known ef-
fective means of avoiding selection bias and confounding.
However, it must be noted that randomized trials have a
number of drawbacks. First, whereas internal validity
(measurement of what it sets out to measure) is likely if a
randomized controlled trial is well designed and con-
ducted, external validity (ability to generalize results to the
broader population) is not guaranteed. The strict inclu-
sion criteria in many trials result in groups that may not
be representative of the broader population. Furthermore,
trial participants who are often volunteers tend to differ
from nonparticipants.17 Second, ethical considerations
make the randomized controlled trial design inappropri-
ate in many instances. Finally, randomized controlled tri-
als can be extremely expensive, limiting their use.
A number of key elements characterize randomized
controlled trials: randomization, allocation concealment,
blinding, analysis and reporting, and validity.
Randomization is the hallmark of randomized con-
trolled trials. It is the method of assigning patients to
groups in such a way that the characteristics of the patients
do not affect the group to which they are assigned. To
achieve this end, the investigator allows chance to decide
to which group each patient is assigned. Randomization
ensures that differences in outcomes between comparison
groups are attributable to the intervention alone and not
to known or unknown confounding characteristics. Al-
though randomization does not guarantee that the groups
will be identical in all baseline characteristics, it does en-
sure that any differences between them are due to chance
alone. Randomization also facilitates concealment of an
intervention from patients and investigators to further
reduce bias. Finally, randomization leads to treatment
groups that are random samples of the study population,
permitting the use of standard statistical tests, which are
based on probability theory.
Goetzinger et al—Prenatal Diagnostic Imaging Studies: Approach to Study Design
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The most basic means of randomization is “toss of the
coin.” More commonly used methods include random ta-
bles and computer-generated randomization sequences.
Blocking, stratification, and minimization are modifications
to simple randomization. Blocking is used to ensure that
numbers of patients in each group are similar at all times. In
block randomization, a chosen number of patients (blocks)
are randomized at a time. Stratification is aimed at ensuring
that groups of patients receiving different interventions are
similar with respect to important prognostic factors. Because
simple randomization does not guarantee that groups would
be similar with regard to all factors (especially in a small trial),
stratified randomization may be used. This process involves
the creation of separate randomization for each subgroup
(stratum) based on an important prognostic factor. For ex-
ample, in a trial of treatments for reducing preterm birth, the
investigator may want to take multiple gestations into ac-
count. Randomization may therefore be performed sepa-
rately for singleton and multiple pregnancies. Minimization
is used in small studies with several important prognostic
variables, in which stratified allocation may not be feasible
for all of the important prognostic variables. It involves as-
signing the next patient entering the trial in a way that min-
imizes the overall imbalance between the groups at that stage
of the trial based on specified prognostic variables.
Blinding attempts to avoid bias by keeping patients, in-
vestigators, or both unaware of the group to which the pa-
tients are assigned. A patient’s response may be affected by
knowing to which group the patient is assigned, either through
a belief that a particular treatment is or is not beneficial or
through a desire to please the investigator. Furthermore, an in-
vestigator’s evaluation may be affected by knowing to which
group a patient is assigned. Thus, it is best if neither the pa-
tient nor the investigator knows to which group the patient is
assigned (double blinding). Sometimes it is only possible for
one party to be unaware of the assignment, in which case the
trial is single blind. Most often, only the patient is blinded be-
cause it is often impossible for the investigator to be unaware
of the treatment. In some cases, blinding is not possible for ei-
ther patients or investigators, and the study is said to be un-
blinded. Even when blinding is not possible, assessment of
outcomes may still be done in a blinded fashion. For example,
in the Management of Myelomeningocele Study,18 in which
outcomes in fetuses with myelomeningocele undergoing pre-
natal or postnatal surgery were compared, the patients and
investigators could not be blinded. However, assessment of
the level of the lesion on magnetic resonance imaging and the
mental and motor function of the patients was determined in
a blinded fashion by individuals who were unaware of the
group allocation of the patients.18
Allocation concealment has a related but conceptu-
ally different goal from blinding. It refers to techniques
used to implement a randomization sequence, in which the
interventions are made indistinguishable to the patients
and investigators. This situation may be achieved through
the use of sequentially numbered opaque sealed envelopes,
pharmacy control, numbered or coded containers, or cen-
tral randomization. Allocation concealment has an impact
on trial results. For example, trials with inadequate alloca-
tion concealment have been shown to yield up to 40%
larger estimates of effect size and are associated with
greater heterogeneity in results.19
In terms of analysis and reporting, it is crucial that ran-
domized controlled trials are not only well designed and
conducted but analyzed and reported in sufficient detail to
enable readers to assess the quality of their conduct and va-
lidity of the study results. The Consolidated Standards of
Reporting Trials is a concerted attempt to improve the qual-
ity of reporting of randomized trials.20 Readers are referred
to the most recent update of the Consolidated Standards
of Reporting Trials statement for details.21 We highlight 4
elements: intention-to-treat analysis, analysis of baseline
characteristics, adjusted analysis, and subgroup analysis.
Intention-to-treat analysis involves analysis of patients
according to the group in which they were originally as-
signed regardless of whether they received or adhered to
the intervention. This approach is in contrast to “per-pro-
tocol analysis” or “as-treated analysis,” in which patients are
analyzed by the intervention actually received. The primary
results of a randomized control trial always should be ana-
lyzed according to the intention-to-treat principle. This
process avoids bias that may result from noncompliance
with the intervention due to unpleasant side effects or lack
of a benefit. In addition, whereas intention-to-treat analysis
often results in a more conservative estimate of effect size,
it allows a better estimate of the effectiveness and implica-
tions of a practice change rather than pure efficacy alone.22
Baseline characteristics are collected at enrollment
in trials. They are used to determine whether the ran-
domization procedure successfully results in comparable
groups, to adjust treatment effects for variables strongly re-
lated to the outcome, to perform subgroup analysis, and to
assess the generalizability of trial results. Investigators often
use formal statistical tests to compare baseline character-
istics between intervention groups. Although a detailed de-
scription of trial participants is important, significance tests
for baseline differences are considered inappropriate, given
that the hypothesis that the groups come from different
populations is known to be false.23 Because the groups are
obtained by randomization, any differences are due to
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chance or flawed randomization. The multiplicity of com-
parisons in baseline characteristics also inflates the type I
error; thus, significant results may occur by chance alone.
Finally, it is argued that nonsignificant differences in strong
predictors will have a more significant effect on the effect
size than significant differences in factors unrelated to the
outcome.23 For these reasons, it is recommended that for-
mal statistical comparison of baseline characteristics be
limited to a few variables known to be strong predictors of
the primary outcome.10
Adjustment of the effect size for baseline variables is
controversial. Although an adjusted analysis may produce
more precise estimates, results are more difficult to inter-
pret than a simple unadjusted analysis. Adjustment for co-
variates in clinical trials is recommended only when there
is clear a priori evidence that some baseline factors are
strong predictors of the outcome, when the outcome is nu-
meric and its baseline value is measured, and when the trial
is small and imbalances are sufficiently large to bias the
effect size.10
Subgroup analysis in clinical trials is common but
often flawed, with results commonly overinterpreted.23 Be-
cause trials are often not designed to test subgroup effects,
it is recommend that subgroup analysis only be conducted
if there is a clear a priori hypothesis and biological plausi-
bility that intervention effects differ between different sub-
groups. It is also important that subgroup analysis include
formal tests of interaction rather than assuming that a
significant effect in one subgroup and not the other is
conclusive evidence that the treatment effect differs 
between the subgroups.10 Finally, results of subgroup
analysis should be interpreted with caution, unless they are
supported by strong evidence of biological plausibility.
A classic example of a randomized clinical trial in pre-
natal imaging is the Routine Antenatal Diagnostic Imaging
With Ultrasound trial.24 This clinical trial of 15,530 women
was designed to test the hypothesis that screening sonogra-
phy in low-risk pregnancies would improve the perinatal out-
come. Pregnant women without any specific indication were
randomized to receive either 2 screening prenatal ultrasound
examinations or routine obstetric care. The trial found no
clinically significant benefit from routine screening ultra-
sound examinations.24 The trial still remains the largest de-
voted to the study question but also illustrates some of the
potential limitations of randomized trials discussed above.
Variations of Randomized Controlled Trials
There are variations of simple parallel-group randomized
controlled clinical trials in which the groups of patients are
studied concurrently.
The crossover randomized trial is one in which pa-
tients serve as their controls. Each patient receives inter-
ventions in sequence, and the order of interventions is
decided at random for each patient. A major advantage of
the crossover design is that comparisons are more effi-
ciently made within patients rather than between patients,
which is particularly useful for outcomes that are highly
variable between patients and when the effect of the inter-
vention can be assessed quickly. The analysis of results
must take into account this particular design by using sta-
tistical methods for paired data. Crossover trials have lim-
itations. For example, they cannot be used for conditions
that can be cured by the intervention. There is also con-
cern of a “carryover effect,” in which there is a residual in-
fluence of the intervention from one period to the other.
This situation may require a “wash-out” period between
interventions.
Cluster randomized trials involve allocating entire
groups (clusters) rather than individual patients to inter-
ventions. The clusters must be taken into account in study
design and data analysis. For example, cluster trials require
larger sample sizes because the use of clusters is associated
with reduced statistical power compared to the traditional
parallel group randomized clinical trial design. Analysis
must also include a cluster coefficient, which takes into ac-
count correlations between patients within the clusters.
The factorial clinical trial design is one in which several
exposure factors are compared at the same time. In this de-
sign, each patient receives a combination of exposures such
that all combinations are received by some patients. Fac-
torial designs are particularly suited to the investigation of
factor interactions, and they are often powered to detect
interactions rather than main factor effects. Factorial clin-
ical trial designs are sometimes proposed to optimize sta-
tistical power when the number of patients available for a
study and resources are limited. However, the use of the
factorial design for this purpose is based on the assump-
tion of no interactions between the factors that may not be
true. In addition, main factor effects from factorial trials
represent averages of all combinations of the other factors,
which may not be meaningful. These variations of ran-
domized clinical trials have rarely been used in prenatal
imaging studies but are included here to be complete. 
Nonrandomized Trials
In some cases, practical, ethical, and other considerations
may preclude the use of a randomized controlled trial. In
such cases, a number of alternatives are available to evalu-
ate interventions. Nonrandomized trials may be per-
formed, in which patients are assigned to groups based on
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reasons other than chance. Inference regarding the impact
of the intervention in such designs is difficult to isolate from
the effects of other factors. Analysis of data from such tri-
als will need to be adjusted for potential confounders. Pre-
post comparisons involve comparing rates of outcomes in
a group before (preintervention) and after (postinter-
vention) implementation of an intervention. This design
technique is weak for showing the effectiveness of an in-
tervention because risk factors and outcomes may change
over time independent of the intervention.
Conclusions
Several research designs are available as tools for prenatal
diagnostic imaging research. The choice of research design
should be made carefully on the basis of the research ques-
tion, the exposure and outcome, ethics, and the availability
of resources. It must be noted that each design has unique
advantages and disadvantages as well as critical elements,
which must be carefully considered. It is important that a
plan for statistical analysis be considered at the design stage
of a study because flaws in design and data collection can-
not be remedied after the fact with statistical analysis.
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